FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS
Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.
1 - 54 . (canceled)
55 . A method of providing increased bioavailability of a cannabinoid with an aqueous solubility of less than 0.1 mg/ml in an oral formulation when administered to a subject wherein the method comprises
adding an N-acylated fatty amino acid or a salt thereof comprising the formula:
to the oral formulation
wherein X and Z are independently hydrogen, a monovalent cation, a divalent metal cation, or an organic cation
thereby providing increased bioavailability of the cannabinoid when administered to the subject as compared to the same oral formulation without the added N-acylated fatty amino acid or salt thereof,
wherein the oral formulation is a suspension, a solution, a tablet, or a capsule.
56 . The method of claim 55 , wherein the N-acylated fatty amino acid or a salt thereof comprises N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).
57 . The method of claim 55 , wherein X is hydrogen, a monovalent cation comprising sodium or potassium, a divalent metal cation comprising calcium or magnesium, or an organic cation comprising tetramethylammonium.
58 . The method of claim 55 , wherein Z is hydrogen, a monovalent cation comprising sodium or potassium, or a divalent cation comprising calcium or magnesium.
59 . The method of claim 55 , wherein X is hydrogen and Z is hydrogen.
60 . The method of claim 55 , wherein X is hydrogen and Z is sodium.
61 . The method of claim 55 , wherein X is sodium and Z is sodium.
62 . The method of claim 55 , wherein the cannabinoid comprises Tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA) and/or mixtures thereof.
63 . The method of claim 55 , wherein the cannabinoid comprises THC and/or CBD.
64 . The method of claim 55 , wherein the oral formulation further comprises flavonoid compounds, terpenes, or terpenoids.
65 . An oral formulation comprising:
a cannabinoid with an aqueous solubility of less than 0.1 mg/ml,
an N-acylated fatty amino acid or a salt thereof comprising the formula:
wherein X and Z are independently hydrogen, a monovalent cation, a divalent metal cation, or an organic cation, and
wherein the oral formulation is a suspension, a solution, a tablet, or a capsule.
66 . The oral formulation of claim 65 , wherein the N-acylated fatty amino acid or a salt thereof comprises N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).
67 . The oral formulation of claim 65 , wherein X is hydrogen, a monovalent cation comprising sodium or potassium, a divalent metal cation comprising calcium or magnesium, or an organic cation comprising tetramethylammonium.
68 . The oral formulation of claim 65 , wherein Z is hydrogen, a monovalent cation comprising sodium or potassium, or a divalent cation comprising calcium or magnesium.
69 . The oral formulation of claim 65 , wherein X is hydrogen and Z is hydrogen.
70 . The oral formulation of claim 65 , wherein X is hydrogen and Z is sodium.
71 . The oral formulation of claim 65 , wherein X is sodium and Z is sodium.
72 . The oral formulation of claim 65 , wherein the cannabinoid comprises Tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA) and/or mixtures thereof.
73 . The oral formulation of claim 65 , wherein the cannabinoid comprises THC and/or CBD.
74 . The oral formulation of claim 65 , wherein the oral formulation further comprises flavonoid compounds, terpenes, or terpenoids.